Tumore della prostata metastatico e resistente alla castrazione

from Salute e Società · host Marco Caracciolo

Dal congresso annuale dell'ASCO, American Society of Clinical Oncology, una buona notizia per il trattamento del tumore della prostata metastatico e resistente alla castrazione. La terapia nota con la sigla 177Lu-PSMA-617, basata su un nuovo radiofarmaco, quando aggiunta al trattamento standard permette di migliorare in modo significativo la sopravvivenza globale. Danilo Magliano ne ha parlato con Giuseppe Procopio, Responsabile Oncologia Medica genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Episode metadata supplied by the publisher feed · Published Jun 12, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

Tumore della prostata metastatico e resistente alla castrazione

0:00 6:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Salute e Società?

This episode is 6 minutes long.

When was this Salute e Società episode published?

This episode was published on June 12, 2021.

Can I download this Salute e Società episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!